Study measures patient rankings of third-line OAB treatments

Findings from the study showed a clinical response rate of 76.4% and 78.4% at 6- and 12-months following activation of the device among patients in the intent-to-treat population.

On this podcast, Bristol Whiles, MD, discusses her urology residency experience at the Kansas University School of Medicine Department of Urology.

"Even the possibility of something really big and revolutionary can still be exciting even if we're in the early stages," says Colin Goudelocke, MD.

“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.

In the intervention group, the HRQOL score changed by 23.9 points between baseline and week 13, from 18.4 to 29.5.

Tepidimonas was notably associated with more severe urinary incontinence episodes, suggesting a potential marker for identifying individuals at risk for more severe symptoms.